Detailed Narrative
Strategic Transformation and XOMA Acquisition
Ligand has undergone a significant financial transformation since 2022, focusing on a royalty aggregation strategy. The recent acquisition of XOMA Royalty, the largest in company history, adds over 120 assets, including 7 commercial and 14 late-stage clinical programs, significantly diversifying and extending the duration of Ligand's royalty portfolio. This acquisition is expected to be immediately accretive, contributing approximately $0.50 to adjusted EPS in H2 2026 and $1.50 in 2027, while reducing XOMA's annual operating expenses from $30 million to less than $5 million.
Strengthened Financial Position and Capital Allocation
The company successfully completed a $700 million 0% coupon convertible note offering, enhancing its balance sheet and providing flexibility for future business development. This financing, combined with strong operating cash flow expected to reach $300 million in 2027, provides approximately $700 million in deployable capital. Ligand also repurchased 229,000 shares for $60 million, demonstrating confidence in its intrinsic value and offsetting potential dilution from the convertible hedge.
Diversified Portfolio and Catalyst-Rich Pipeline
Post-XOMA acquisition, Ligand's commercial portfolio now includes over 40 royalty revenue-generating products with 15 key programs, spanning diverse therapeutic areas. The company anticipates a "most catalyst-rich period" over the next 18 months, with up to 7 pivotal trial readouts, potential FDA approvals, label expansions, and geographic launches. This broad diversification aims to make the business resilient to binary clinical risks, with success not dependent on a single product.
Key Commercial Royalty Drivers
Filspari, approved in April for FSGS, demonstrated 96% YoY growth in Q2 US net sales to $141 million, with partner Travere reiterating potential peak sales exceeding $3 billion. Ohtuvayre sales grew 98% YoY to $204 million. New additions from XOMA, Vabysmo and Ojemda, are expected to be significant contributors. Vabysmo had H1 2026 sales of $2.6 billion, with analyst consensus peak sales of $7 billion. Ojemda, with Day One's 2026 sales guidance of $225-$250 million, has analyst consensus peak sales exceeding $1 billion.
Pipeline Progress and Regulatory Updates
Palvella is on track to complete a rolling NDA submission for Rapamycin in microcystic lymphatic malformations by end of 2026, with potential approval in 2027. Agenus is discontinuing its current Phase III Bot/Bal trial in relapsed/refractory colon cancer, initiating a new neoadjuvant study in Q1 2027. Mirum's Volixibat, despite positive Phase IIb data in PSC, received an FDA recommendation for a Phase III trial, pushing out its approval timeline, though the PBC study remains on track for Q1 2027 readout.
Tax Attributes and Milestone Opportunities
The XOMA acquisition brings over $110 million in Section 174 tax credits and net operating losses, expected to be utilized over the next 3 to 5 years, resulting in significant US cash tax savings. Additionally, the acquired portfolio includes approximately $2.3 billion in publicly disclosed potential milestone opportunities, ranging from preclinical to late-stage, which represent embedded economic upside over time⏳. The company plans to provide more detail on these at its Investor Day in December.